These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Screening and diagnosis of fetal neural tube defects, abdominal wall defects and Down's syndrome. With special reference to biochemical and ultrasound screening in the second trimester of pregnancy and to early amniocentesis. Jørgensen FS Dan Med Bull; 2001 Aug; 48(3):127-45. PubMed ID: 11556264 [No Abstract] [Full Text] [Related]
26. Biochemical screening for chromosomal disorders and neural tube defects (NTD): is adjustment of maternal alpha-fetoprotein (AFP) still appropriate in insulin-dependent diabetes mellitus (IDDM)? Sancken U; Bartels I Prenat Diagn; 2001 May; 21(5):383-6. PubMed ID: 11360279 [TBL] [Abstract][Full Text] [Related]
27. The ABCs of pre-, neo-, and post-natal testing. Grenache DG; Karon B; Ernst D MLO Med Lab Obs; 2009 Sep; 41(9):10, 12, 14-8 passim; quiz 22-3. PubMed ID: 19877396 [No Abstract] [Full Text] [Related]
28. FDA study finds test kits effective in spotting birth defects. Public Health Rep; 1998; 113(5):382. PubMed ID: 9769758 [No Abstract] [Full Text] [Related]
30. Second-trimester maternal serum screening for Down syndrome in Mainland China. Liao C; Huang Y; Li D; Song S; Yi C; Zhou J Prenat Diagn; 2006 Dec; 26(13):1271-2. PubMed ID: 17139699 [No Abstract] [Full Text] [Related]
31. [Screening by maternal serum markers for Down's syndrome]. Liu JT; Hao N; Sun NH; Wang FY; Xu YH; Gai MY; Bian XM; Yang JQ Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):156-9. PubMed ID: 12905710 [TBL] [Abstract][Full Text] [Related]
32. A cost-effectiveness analysis of prenatal screening strategies for Down syndrome. Odibo AO; Stamilio DM; Nelson DB; Sehdev HM; Macones GA Obstet Gynecol; 2005 Sep; 106(3):562-8. PubMed ID: 16135588 [TBL] [Abstract][Full Text] [Related]
33. Down's syndrome risk estimates demonstrate considerable heterogeneity despite homogeneity of input. Reynolds T; Ellis A; Jones R Ann Clin Biochem; 2004 Nov; 41(Pt 6):464-8. PubMed ID: 15588435 [TBL] [Abstract][Full Text] [Related]
34. Prenatal screening tests facilitate risk assessment. Miller SM; Isabel JM MLO Med Lab Obs; 2002 Feb; 34(2):8-11, 14-6, 19; quiz 20-1. PubMed ID: 11881274 [TBL] [Abstract][Full Text] [Related]
35. [Trisomy 21 screening: value of ultrasound and serum markers in a combined approach]. Senat MV; Rozenberg P; Bernard JP; Ville Y J Gynecol Obstet Biol Reprod (Paris); 2001 Feb; 30(1):11-27. PubMed ID: 11240502 [No Abstract] [Full Text] [Related]
36. Prenatal screening and diagnosis for pediatricians. Cunniff C; Pediatrics; 2004 Sep; 114(3):889-94. PubMed ID: 15342871 [TBL] [Abstract][Full Text] [Related]
38. Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. Spencer K Prenat Diagn; 2000 Aug; 20(8):652-6. PubMed ID: 10951476 [TBL] [Abstract][Full Text] [Related]
39. Down syndrome maternal serum marker screening after 18 weeks' gestation. Muller F; Dreux S; Oury JF; Luton D; Uzan S; Uzan M; Levardon M; Dommergues M Prenat Diagn; 2002 Nov; 22(11):1001-4. PubMed ID: 12424764 [TBL] [Abstract][Full Text] [Related]
40. The routinization of prenatal testing. Suter SM Am J Law Med; 2002; 28(2-3):233-70. PubMed ID: 12197464 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]